European Archives - Page 1459 of 1486 - European Medical Journal

Review: Genetics of Urolithiasis

Urolithiasis constitutes a worldwide health problem with a frequency of up to 15% in the general population.

Review: Evolution of Minimally Invasive Radical Prostatectomy – A Continuous Development

During the last 15 years, minimally invasive surgery has been introduced gradually in surgical treatment for prostate cancer (CaP).

EMJ

Stigma is a Side-Effect of HIV Prevention Medicine

100,000 people are living with HIV within the UK, and one-quarter of these are undiagnosed. This is not only within the capital; latest research suggests…

EMJ Hepatology 1[Suppl 1] 2014

The main objective of chronic hepatitis C virus (HCV) management is to provide high viral eradication rates with acceptable toxicity.

EMJ

European Commission Grants Marketing Authorisation for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma

Foster City, CA, 19 September 2014 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing…

Can Primary Care Physicians Manage Benign Prostatic Hyperplasia Patients As Urologists Do?

Most clinical practice guidelines (CPGs) assume that general practitioners (GPs) can manage non- complicated benign prostatic hyperplasia (BPH)-related…

A Very Rare Entity of Benign Prostatic Inflammation: Xanthogranulomatous Prostatitis

Prostatitis is a commonly seen clinical entity in daily urological practice.

EMJ

Advancements and Updates in the Field of Enuresis

Summary of the Enuresis Lecture, held at the 25th Annual ESPU Congress, Innsbruck, Austria, on 9th May 2014

EMJ

EMJ Urology 1 [Suppl 1] 2014

Dr Austin’s presentation aimed to provide a state-of-the-art review on enuresis, focusing on diagnosis, treatment strategies, and management of…

EMJ

Update: Diagnosis and Treatment of Muscle-Invasive and Metastatic Bladder Cancer in 2014

Bladder cancer (BC) is the ninth most commonly diagnosed malignant tumour in the world, with an incidence of about 356,000 and a mortality of about 145,000 per year in both non-muscle-invasive and muscle-invasive BC.